Subscribe to RSS
DOI: 10.1055/s-0031-1298301
© Georg Thieme Verlag KG Stuttgart · New York
Pharmacokinetics of Valerenic Acid in Rats after Intravenous and Oral Administrations
Publication History
received October 7, 2011
revised January 3, 2012
accepted January 24, 2012
Publication Date:
12 March 2012 (online)

Abstract
Valerenic acid (VA), a sesquiterpenoid, is one of the major secondary bioactive metabolites of Valeriana officinalis L. Until now in vivo studies on the absorption, bioavailability, disposition, and metabolism of VA are limited. We established and validated an LC-MS/MS assay for the determination of VA in rat plasma and successfully used this method for pharmacokinetic studies in rats after intravenous (i. v.) and oral administrations. The plasma concentration-time data was analyzed by both non-compartmental and compartmental approaches using WinNonlin software. Following i. v. administration, the disposition of VA in rat plasma was biphasic, subdivided into a fast distribution and a slow elimination phase. The half-life of the distribution phase was 6–12 min, and that of the terminal elimination phase 6–46 h, indicating a possible large tissue binding. Disposition PK of valerenic acid after oral treatment was also described by a two-compartment model with a clearance (CL/F) of 2–5 L · h−1 · kg−1 and volume of distribution of (Vd) 17–20 L · kg−1. The extent of absorption (F) after oral administration was estimated to be 33.70 % with a half-life of 2.7–5 h. Dose proportionality was observed in terms of dose and AUCs, suggesting linear pharmacokinetics at the dose levels studied in rats.
Key words
Valeriana officinalis - Valerianaceae - valerenic acid - pharmacokinetics - absolute bioavailability - two-compartment model
References
- 1 European Scientific Cooperative on Phytotherapy (ESCOP) .
Valeriana officinalis
. ESCOP Monographs. 2nd edition. Stuttgart: Thieme; 2003: 539-546
MissingFormLabel
- 2
Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S.
Valerenic acid potentiates and inhibits GABAA receptors: molecular mechanism and subunit specificity.
Neuropharmacology.
2007;
53
178-187
MissingFormLabel
- 3
Khom S, Strommer B, Ramharter J, Schwarz T, Schwarzer C, Erker T, Ecker G F, Mulzer J, Hering S.
Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands – in vitro and in vivo characterization.
Br J Pharmacol.
2010;
161
65-78
MissingFormLabel
- 4
Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B.
Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid.
Planta Med.
2008;
74
19-24
MissingFormLabel
- 5
Neuhaus W, Trauner G, Gruber D, Oelzant S, Klepal W, Kopp B, Noe C R.
Transport of a GABAA receptor modulator and its derivatives from Valeriana officinalis L. s. l. across an in vitro cell culture model of the blood-brain barrier.
Planta Med.
2008;
74
1338-1344
MissingFormLabel
- 6
Hendriks H, Bos R, Woerdenbag H J, Koster A S.
Central nervous depressant activity of valerenic acid in the mouse.
Planta Med.
1985;
51
28-31
MissingFormLabel
- 7
Murphy K, Kubin Z J, Shepherd J N, Ettinger R H.
Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats.
Phytomedicine.
2010;
17
674-678
MissingFormLabel
- 8
Benke D, Barberis A, Kopp S, Altmann K H, Schubiger M, Vogt K E, Rudolph U, Mohler H.
GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian
root extracts.
Neuropharmacology.
2009;
56
174-181
MissingFormLabel
- 9
Chow N K, Fretz M, Hamburger M, Butterweck V.
Telemetry as a tool to measure sedative effects of a valerian root extract and its
single constituents in mice.
Planta Med.
2011;
77
795-803
MissingFormLabel
- 10
Anderson G D, Elmer G W, Taibi D M, Vitiello M V, Kantor E, Kalhorn T F, Howald W N, Barsness S, Landis C A.
Pharmacokinetics of valerenic acid after single and multiple doses of valerian in
older women.
Phytother Res.
2010;
24
1442-1446
MissingFormLabel
- 11 FDA .Guidance for industry – bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf Accessed June 4, 2011
MissingFormLabel
- 12
Barve A, Chen C, Hebbar V, Desiderio, Saw C L, Kong A N.
Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol
in rats.
Biopharm Drug Dispos.
2009;
30
356-365
MissingFormLabel
- 13 Davies M, Whitting I J. Numerical methods for non-linear optimization. New York: Academic Press; 1972
MissingFormLabel
- 14
Perry N B, Burgess E J, Lorimer S D, Klink J W.
Fatty acid anilides as internal standards for high performance liquid chromatographic
analyses of Valerian officinalis L. and other medicinal plants.
Phytochem Anal.
1996;
7
263-268
MissingFormLabel
- 15
Maier-Salamon A, Trauner G, Hiltscher R, Reznicek G, Kopp B, Thalhammer T, Jaeger W.
Hepatic metabolism and biliary excretion of valerenic acid in isolated perfused rat
livers: role of Mrp2 (Abcc2).
J Pharm Sci.
2009;
98
3839-3849
MissingFormLabel
Dr. Veronika Butterweck
College of Pharmacy
Department of Pharmaceutics
University of Florida
PO Box 100494
Gainesville, FL 32610
USA
Phone: +1 35 22 73 78 59
Email: butterwk@cop.ufl.edu
Current address:
University of Applied Sciences
School of Life Sciences
Department of Pharmatechnology
Gründenstrasse 40
4132 Muttenz
Switzerland
Email: veronika.butterweck@fhnw.ch